PA
ETNB

PharVision Advisers’s 89bio ETNB Stock Holding History

PharVision Advisers’s Portfolio ETNB Stock Details ETNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-15,124
Closed -$222K – 779
2025
Q3 		$222K Buy
+15,124
New +$154K 0.13% 417

Other funds holding ETNB

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

PharVision Advisers's ETNB Position: Q4 2025 in Review

PharVision Advisers sold out of 89bio (ETNB) in Q4 2025, closing a stake of 15,124 shares — an estimated $222K sold.

PharVision Advisers first reported a position in ETNB in Q3 2025 and held it in 1 quarter. The position peaked at $222K in Q3 2025. 2 funds tracked by Wall St. Rank hold ETNB as of Q4 2025.

  • PharVision Advisers reported no remaining 89bio position as of Q4 2025 after selling out during the quarter.
  • PharVision Advisers sold 15,124 89bio shares in Q4 2025, an estimated $222K.
  • PharVision Advisers first reported a position in 89bio in Q3 2025 and held it in 1 quarter.
  • PharVision Advisers's 89bio position peaked at $222K in Q3 2025.
  • 2 funds tracked by Wall St. Rank held 89bio as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.